155 related articles for article (PubMed ID: 37162620)
1. Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer.
Detert Oude Weme SEH; Hulskotte LMG; Vervenne WL; Imholz ALT; Cremers RGHM; Taxis K; Reyners AKL; van Berlo-van de Laar IRF; Jansman FGA; Benoist GE
Clin Pharmacokinet; 2023 Jul; 62(7):989-996. PubMed ID: 37162620
[TBL] [Abstract][Full Text] [Related]
2. Observations of urinary oxycodone and metabolite distributions in pain patients.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
[TBL] [Abstract][Full Text] [Related]
3. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
[TBL] [Abstract][Full Text] [Related]
4. Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry.
Gaudette F; Sirhan-Daneau A; St-Onge M; Turgeon J; Michaud V
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():174-180. PubMed ID: 26655109
[TBL] [Abstract][Full Text] [Related]
5. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
6. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
[TBL] [Abstract][Full Text] [Related]
7. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
Fang WB; Lofwall MR; Walsh SL; Moody DE
J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
[TBL] [Abstract][Full Text] [Related]
8. Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases.
Pantano F; Brauneis S; Forneris A; Pacifici R; Marinelli E; Kyriakou C; Pichini S; Busardò FP
Clin Chem Lab Med; 2017 Aug; 55(9):1324-1331. PubMed ID: 28080998
[TBL] [Abstract][Full Text] [Related]
9. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
[TBL] [Abstract][Full Text] [Related]
11. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.
Alyamani M; Li J; Patel M; Taylor S; Nakamura F; Berk M; Przybycin C; Posadas EM; Madan RA; Gulley JL; Rini B; Garcia JA; Klein EA; Sharifi N
Ann Oncol; 2020 Mar; 31(3):369-376. PubMed ID: 32057540
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC-MS/MS.
Miyazawa Y; Nakamura T; Takezawa Y; Shimizu N; Matsuo Y; Ogura H; Takei T; Sekine Y; Arai S; Suzuki K
Prostate; 2023 Jun; 83(8):759-764. PubMed ID: 36891746
[TBL] [Abstract][Full Text] [Related]
13. A sensitive LC-MS/MS method for the quantitation of oxycodone, noroxycodone, 6α-oxycodol, 6β-oxycodol, oxymorphone, and noroxymorphone in human blood.
Truver MT; Jakobsson G; Chermà MD; Swortwood MJ; Gréen H; Kronstrand R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1171():122625. PubMed ID: 33744597
[TBL] [Abstract][Full Text] [Related]
14. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry.
Neuvonen M; Neuvonen PJ
Ther Drug Monit; 2008 Jun; 30(3):333-40. PubMed ID: 18520605
[TBL] [Abstract][Full Text] [Related]
15. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.
van Nuland M; Bergman AM; Rosing H; de Vries N; Huitema ADR; Beijnen JH
Pharmacotherapy; 2019 Dec; 39(12):1137-1145. PubMed ID: 31596947
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
17. A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone.
Hulskotte LMG; Wilbrink-Pijffers I; Arbouw MEL; Benoist GE; Jansman FGA; van Berlo-van de Laar IRF
Biomed Chromatogr; 2024 Apr; ():e5874. PubMed ID: 38587098
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
Joulia ML; Carton E; Jouinot A; Allard M; Huillard O; Khoudour N; Peyromaure M; Zerbib M; Schoemann AT; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Clin Genitourin Cancer; 2020 Apr; 18(2):155-160. PubMed ID: 31630979
[TBL] [Abstract][Full Text] [Related]
19. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
Edwards SR; Smith MT
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):264-70. PubMed ID: 17098487
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling.
Al-Qurain AA; Williams DB; Mackenzie L; Roberts MS; Wiese MD
J Pharm Biomed Anal; 2021 Sep; 203():114171. PubMed ID: 34087551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
